1-pyridin-2-yl-3-pyridin-3-yl-propenone | 18461-21-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-pyridin-2-yl-3-pyridin-3-yl-propenone
• 英文别名: (E)-3-pyridin-3-yl-1-pyridin-2-yl-propenone；(E)-1-pyridin-2-yl-3-pyridin-3-ylprop-2-en-1-one
• CAS: 18461-21-7
• 化学式: C₁₃H₁₀N₂O
• mdl: MFCD00223965
• 分子量: 210.235
• InChiKey: AQIFCKDIMWXKDX-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-pyridin-2-yl-3-pyridin-3-yl-propenone 、 在 ammonium acetate 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以70%的产率得到2-Phenyl-4,6-bis(6-pyridin-2-yl-4-pyridin-3-ylpyridin-2-yl)pyrimidine
  参考文献：
  名称：

  Supramolecular Assemblies of a Bis(terpyridine) Ligand and of its [2×2] Grid-type ZnII and CoII Complexes on Highly Ordered Pyrolytic Graphite

  摘要：

  The synthesis and characterisation of bis(terpyridine)-derived ligands which are capable of forming [2 x 2] grid-like complexes is presented. Additional pyridine substituents on these ligands do not interfere with the complexation process. Adsorbing one of the pure ligands on highly ordered pyrolytic graphite (HOPG) shows a highly ordered structure stabilised by additional weak intermolecular C-H... N hydrogen bonds partially through the extra-pyridines as could be shown by scanning tunneling microscopy (STM) investigations. Similar adsorption experiments with one of the corresponding [2 x 2] Co-11 grid- type complexes on graphite, led also to a well-organised structure with interdigitation of the extra-pyridine moieties.

  DOI：

  10.1002/1521-3765(20020215)8:4<951::aid-chem951>3.0.co;2-9

文献信息

• Organic compounds
  申请人：Adcock Claire

  公开号：US20090215776A1

  公开（公告）日：2009-08-27

  Compounds of formula I in free or salt or solvate form, where T 1 , T 2 , X, R a , R b , R 8 and R 9 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  式I的化合物以自由形式、盐形式或溶剂合形式存在，其中T1、T2、X、Ra、Rb、R8和R9的含义如规范中所示，可用于治疗炎症或阻塞性气道、肺动脉高压、肺纤维化、肝纤维化、肌肉疾病和全身骨骼疾病。还描述了含有这些化合物的药物组合物和制备这些化合物的方法。
• Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition
  申请人：Gupta K. Shyam

  公开号：US20060074108A1

  公开（公告）日：2006-04-06

  This invention relates to compounds that are selective inhibitors of Matrix Metalloprotease (also known as Matrix Metalloproteinase, MMP), to cosmetic and pharmaceutical compositions containing them, and to their use in the prevention and/or treatment of ailments associated with MMP, including inflammation, wound healing, skin aging, skin tone discoloration, body odor, oral cavity odor, rosacea, acne, and hair growth modulation.

  本发明涉及基质金属蛋白酶（又称基质金属蛋白酶，MMP）选择性抑制剂的化合物、含有这些化合物的化妆品和药物组合物，以及它们在预防和/或治疗与 MMP 有关的疾病中的用途，包括炎症、伤口愈合、皮肤老化、肤色变色、体味、口腔异味、酒渣鼻、痤疮和毛发生长调节。
• ORGANIC COMPOUNDS
  申请人：Novartis AG

  公开号：EP2242742A2

  公开（公告）日：2010-10-27
• PYRIDINE DERIVATIVES
  申请人：Novartis AG

  公开号：EP2242742B1

  公开（公告）日：2015-12-02
• US8343966B2
  申请人：——

  公开号：US8343966B2

  公开（公告）日：2013-01-01